NSCLC - Non Small Cell Lung Cancer Now Closed
KEYNOTE-598 / MK-3475-598 - Hosted By elie
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive
| Study Type | Treatment |
| Sponsor Name | Merck |
| Disease type | Non-Small Cell Lung Cancer |
| Disease Stage | IV |
| Clinical Status | First line |
| Phase | III |
| Intervention / Treatment | Pembrolizumab + Ipilimumab vs Ipilumumab + Placebo |
| Research Site | St. Mary’s Hospital |
| Investigator | Dr Adrian Langleben |
| Coordinator | Dora Bartulovic |
| Telephone number | |
| Fax number | – |
| Study start date | October 5, 2017 |
| Study end date | |
| Trial Status | Recruiting |
| Study Type | Treatment |
| Sponsor Name | |
| Tumor Site | NSCLC - Non Small Cell Lung Cancer |
| Disease Stage | Stage IV |
| Clinical Status | Advanced Disease 1st Line |
| Phase | Phase I |
| Intervention / Treatment | |
| Research Site | Montreal, QC, St. Mary's Hospital |
| Investigator | |
| Coordinator | |
| Telephone Number | +1 (514) 345-3511 |
| Fax Number | |
| Study Start Date | |
| Study End Date | |
| Trial Status |
